SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Fate Therapeutics Reports Third-Quarter 2026 Results and Business Updates

The company reported third-quarter 2026 financial results and business updates. The body says a safety profile was presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single [truncated].

FATE
SquawkNews Desk

Related stories

Tripadvisor Reports Third-Quarter Loss of $2.66 per Share M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC Tripadvisor Reports Third-Quarter Revenue of $436.4 Million Tripadvisor reported third-quarter revenue of $436.4 million. M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC Borussia Dortmund Q1 Net Profit Falls to €11.9M Q1 revenue was €107.4M versus €107.0M a year earlier, while net profit fell to €11.9M from €22.9M. The company maintained its 2026/2027 net profit forecast of €0M to €10M. M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC Asian Tech Stocks Tumble in Tokyo and Seoul; Hong Kong Surges South Korea’s KOSPI fell 5.3%, while Japan’s Nikkei 225 also declined. Hong Kong shares rose. M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC Lexicon Pharmaceuticals Reports Q3 2026 Revenue of $11.3 Million Lexicon reported a net loss of $14.0 million, or $0.03 per share, and ended September with $183.2 million in cash and investments. Revenue was $11.3 million, compared with $14.2 mi M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC CareCloud reports third-quarter revenue of $33.7 million M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC